Access Management: Programs that Facilitate Access
Bristol-Myers Squibb has developed specific programs and partnerships to help facilitate and manage access to our medicines in a variety of ways and in many parts of the developing world. Access is also maintained and expanded by Bristol-Myers Squibb through technology transfer agreements covering many developing world nations.
Hepatitis C (HCV) Developing World Strategy: In 2014, Bristol-Myers Squibb announced its approach to help increase access to one of its hepatitis C (HCV) medicines, daclatasvir, in the developing world. The strategy includes tiered pricing and voluntary licensing, and is built on the fundamental belief that sustainable access to treatment and care in the developing world requires a coalition of multisectoral stakeholders to work together to address HCV. Read more about our HCV Developing World Strategy.
HIV Global ACCESS Program: Since 2000, Bristol-Myers Squibb has operated a multifaceted program designed to improve access to HIV medicines in countries that are among the most significantly impacted by the pandemic and have the fewest resources to combat it. The program rests upon three pillars:
- Antiretroviral pricing that reflects no profit for the company in sub-Saharan Africa and low-income countries;
- An HIV medicines patent policy that reflects a commitment to access through generic manufacturer participation in many countries; and
- Partnering with others who share in a commitment to the fight against HIV/AIDS.
The goal of the Bristol-Myers Squibb Global Access Program is to enable broad access to our HIV medicines in regions most severely impacted by HIV and with limited ability to pay. Videx, Zerit and Reyataz are currently available through the Bristol-Myers Squibb Global Access Program.
- In 2001, Bristol-Myers Squibb announced that it would provide its HIV medicines at no-profit pricing in sub-Saharan Africa. The Access Program was extended to most low income countries in 2004. Currently, 66 countries in Africa, Asia, and Latin America are eligible for Access Program pricing.
- Prices for our HIV medicines in middle income countries are based on a number of factors including affordability (using the World Bank GNI/capita metric) and government commitment to the treatment of HIV/AIDS. The company continues to work with UN agencies and governments of middle income countries to assess appropriate means of supporting national HIV treatment and scale-up efforts.
At the same time, we continue to focus our R&D efforts across a number of HIV/AIDS programs, and work with health care authorities worldwide to help ensure appropriate access to current therapies. Procurement groups that participate in the HIV Global ACCESS program include the Clinton Foundation, UNICEF, the International Development Authority, the Partnership for Supply Chain Management, Medecins Sans Frontieres and other global, regional and local organizations.
HIV Global ACCESS Policy Statement
Bristol-Myers Squibb Statement on Access to HIV/AIDS Medicines in Sub-Saharan Africa, and Developing and Low-Income Countries
Direct Import Program: Idis, a U.K.-based leader in named patient programs, works with Bristol-Myers Squibb to help patients with unmet medical needs gain access to potentially life-saving medicines. Idis’s work for Bristol-Myers Squibb spans 94 countries on four continents and involves 11 products. The company’s Direct Import Policy governs product availability.
Expanded Access Program: Bristol-Myers Squibb provides access to certain investigational therapies for patients with serious or life-threatening diseases through its Expanded Access Programs. The program is designed to help patients who have exhausted all other treatment options by supplying products with promising Phase 3 clinical data but for which marketing authorization in a particular country has not yet been received.
Post Study Drug Program: This program serves the needs of certain former Bristol-Myers Squibb clinical study subjects who have serious and/or life-threatening diseases. To be eligible, an individual must have a serious and/or life-threatening disease state; complete a Bristol-Myers Squibb-sponsored clinical trial (excluding Early Access or Expanded Access and Compassionate Use programs and studies that are terminated early); be clinically benefiting and medically stable on the regimen; and be in financial need. The medicines a patient will be eligible to receive through the program are limited to those used in the clinical trial and that are marketed locally. Investigational products are not supplied through the Post-Study Drug Program.